亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Edoxaban, Rivaroxaban, or Apixaban for Cancer-Associated Venous Thromboembolism in the Real World: Insights from the COMMAND VTE Registry-2

医学 拜瑞妥 依杜沙班 阿哌沙班 内科学 静脉血栓栓塞 重症监护医学 癌症 血栓形成 华法林 心房颤动
作者
Daisuke Sueta,Yugo Yamashita,Takeshi Morimoto,Ryuki Chatani,Yuji Nishimoto,Kazuhisa Kaneda,Nobutaka Ikeda,Yohei Kobayashi,Satoshi Ikeda,Kitae Kim,Moriaki Inoko,Toru Takase,Shuhei Tsuji,Maki Oi,Takuma Takada,Kazunori Otsui,Jiro Sakamoto,Yoshito Ogihara,Takeshi Inoue,Shunsuke Usami,Po‐Min Chen,Kiyonori Togi,Norimichi Koitabashi,Seiichi Hiramori,Kosuke Doi,Hiroshi Mabuchi,Yoshiaki Tsuyuki,Koichiro Murata,Kensuke Takabayashi,Hisato Nakai,Wataru Shioyama,Tomohiro Dohke,Ryusuke Nishikawa,Takeshi Kimura,Kenichi Tsujita
出处
期刊:Thrombosis and Haemostasis [Georg Thieme Verlag KG]
被引量:1
标识
DOI:10.1055/a-2316-5269
摘要

Background Real-world data on clinical characteristics and outcomes related to the use of different direct oral anticoagulants (DOACs) for cancer-associated venous thromboembolism (VTE) is lacking. Methods The COMMAND VTE Registry-2 is a multicenter registry enrolling 5,197 consecutive patients with acute symptomatic VTE from 31 centers in Japan from January 2015 to August 2020. Our study population comprised 1,197 patients with active cancer who were divided into the edoxaban (N = 643, 54%), rivaroxaban (N = 297, 25%), and apixaban (N = 257, 22%) groups. Results The cumulative 5-year incidence of recurrent VTE (9.3, 10.2, and 8.5%, respectively, p = 0.82) and all-cause death (67.5, 66.8, and 63.8%, respectively, p = 0.22) did not differ among the groups. Despite adjusting for confounders, the risks of recurrent VTE and all-cause death did not differ significantly among the groups. The cumulative 5-year incidence of major and clinically relevant bleeding was significantly lower in the rivaroxaban group than those in the other groups (22.6, 14.0, and 22.8%, p = 0.04; and 37.6, 26.8, and 38.3%, p = 0.01, respectively). After adjusting for confounders, in the rivaroxaban group, the risk for major bleeding was numerically lower (hazard ratio [HR]: 0.65, 95% confidence interval [CI]: 0.40–1.01) and that of clinically relevant all bleeding was significantly lower (HR: 0.67, 95% CI: 0.48–0.92) than those in the edoxaban group. Conclusion The risks of recurrent VTE and all-cause death did not differ significantly among the different DOACs ; however, the risk of bleeding events could differ, with a potentially lower risk of bleeding with rivaroxaban.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐应助二三采纳,获得10
2秒前
4秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
小蘑菇应助你怎么讨厌采纳,获得10
9秒前
9秒前
二三发布了新的文献求助10
13秒前
十三月的过客完成签到,获得积分10
23秒前
Banbor2021完成签到,获得积分10
28秒前
8OK完成签到,获得积分10
35秒前
morena发布了新的文献求助10
59秒前
1分钟前
1分钟前
8OK发布了新的文献求助10
1分钟前
ma发布了新的文献求助10
1分钟前
GRG完成签到 ,获得积分10
1分钟前
英俊的铭应助小樊采纳,获得30
1分钟前
Vashon完成签到,获得积分10
1分钟前
1分钟前
毕葛发布了新的文献求助20
1分钟前
1分钟前
1分钟前
48662发布了新的文献求助10
1分钟前
1分钟前
外向板栗发布了新的文献求助10
1分钟前
寻道图强应助科研通管家采纳,获得30
2分钟前
2分钟前
2分钟前
仔仔完成签到 ,获得积分10
2分钟前
morena发布了新的文献求助10
2分钟前
2分钟前
传奇3应助Gavin采纳,获得10
2分钟前
Vashon发布了新的文献求助10
2分钟前
grace完成签到 ,获得积分10
2分钟前
2分钟前
Gavin发布了新的文献求助10
2分钟前
batmanrobin完成签到,获得积分10
2分钟前
愉快无施发布了新的文献求助10
3分钟前
李健应助山南水北采纳,获得10
3分钟前
3分钟前
小樊发布了新的文献求助30
4分钟前
高分求助中
Sustainability in Tides Chemistry 2000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Essentials of thematic analysis 700
A Dissection Guide & Atlas to the Rabbit 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3126089
求助须知:如何正确求助?哪些是违规求助? 2776277
关于积分的说明 7729714
捐赠科研通 2431733
什么是DOI,文献DOI怎么找? 1292230
科研通“疑难数据库(出版商)”最低求助积分说明 622601
版权声明 600392